Reversal agents for non-vitamin K antagonist oral anticoagulants

Key PointsThe non-vitamin K antagonist oral anticoagulants (NOACs) include dabigatran, which inhibits thrombin, and apixaban, betrixaban, edoxaban, and rivaroxaban, which inhibit factor XaThree NOAC reversal agents are in various stages of development: idarucizumab is licensed in many countries, andexanet is under consideration by regulatory agencies, and ciraparantag is undergoing phase III evaluationIdarucizumab is approved for dabigatran …